This study supports the use of dupilumab as a systemic treatment for long-term management of moderate to severe AD without routine laboratory monitoring in clinical practice.
The study adds to the current literature by demonstrating the increased and independent risk for mortality-associated psoriasis, using a nationally representative sample of the US population.
The eventual elimination of chemical testing on mammals was announced by the U.S. Environmental Protection Agency.
Physicians were more likely to prescribe opioids later in the day and when running behind schedule than when appointments were earlier and on-time, according to a study published in JAMA Network Open.
From the patient’s perspective, higher atopic dermatitis severity is associated with poorer HRQoL — a burden that may provide motivation for more effective management of atopic dermatitis.
The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been indicated for patients 12 years of age and older.
Cuts are being proposed for 5 controlled substances based on estimates of diversion.
Educational pop-up windows will now appear on Facebook and Instagram when people search for vaccine-related content.
Notable improvement with dupilumab in the treatment of moderate to severe atopic dermatitis was seen in all racial subgroups.
Low immunohistochemical staining expression of INPP5A predicts poor overall survival in recurrent and metastatic cutaneous squamous cell carcinoma.
Please login or register first to view this content.
